ORIC Pharmaceuticals has stopped pretending to be a multi-asset discovery platform and is now a two-program late-stage oncology company whose entire residual claim sits on whether rinzimetostat can convert a small combination signal in metastatic castration-resistant prostate cancer into a registrational win. Management opened Himalayas-1 after End-of-Phase One talks with the Food and Drug Administration and peer regulators, pairing a four-hundred-milligram once-daily dose with Bayer's darolutamide against physician choice of another androgen-receptor drug or docetaxel. The trial is designed around radiographic progression-free survival, with overall survival as the load-bearing secondary. That design choice, plus a no-cost Bayer supply deal that leaves ORIC with every commercial right, is the event that re-priced the equity from a cash-plus-option story into a Phase Three duration story.
The tension is that the Phase 1b evidence is real and still thin. In the recommended-dose cohort, roughly half of evaluable patients posted a PSA50 decline and most of those with circulating tumor DNA on board saw a deep molecular drop, while landmark radiographic control through five months sat in the mid-eighties. Those figures sit next to a cleaner Grade One and Grade Two safety mix than first-generation EZH2 drugs, which is why the company picked the lower dose. The sample is fifteen to eighteen patients with under five months of median follow-up. Pfizer's mevrometostat is already running a competing PRC2 Phase Three in a similar post-abiraterone setting, so Himalayas-1 is not racing an empty field.
Cash and investments totaled $387.6 million at mid-year. First-quarter ATM proceeds of $59.9 million sit inside that balance and fund the operating plan into the second half of 2028. First-half operating cash use of $64.0 million barely rose from the prior year even as rinzimetostat external spend became the dominant research line, which is the operational proof that last August's discovery shutdown is doing what it was designed to do. The open question is whether autumn enozertinib updates at the European Society for Medical Oncology and in the exon-twenty combination cohorts are strong enough to justify a second registrational start without breaking that runway.